The company's commercial products consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. The company expanded globally with Japan approval for Pompe therapy and plans to launch in 10 new European markets. Pipeline highlights include DMX-200's Phase 3 trial for FSGS and gene therapy advancements, supported by Teva's patent settlement ensuring Galafold's U.S. exclusivity until 2037.
FOLD trades at approximately 6x 2025 revenue estimates with 17 consecutive quarters of double-digit revenue growth and a clear path to profitability in H2 2025. The company demonstrates strong execution in a high-growth rare disease market with validated products and a promising pipeline, though acquisition status creates near-term uncertainty.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →